Showing 1861-1870 of 2123 results for "".
- Long-Term Data from Real-World CLARENCE Study Show Stable Disability Outcomes in Patients with Highly Active Relapsing MS Treated with Mavencladhttps://practicalneurology.com/news/long-term-data-from-real-world-clarence-study-show-stable-disability-outcomes-in-patients-with-highly-active-relapsing-ms-treated-with-mavenclad/2470330/After 5 years of follow-up, people with highly active relapsing multiple sclerosis (RMS) treated with Mavenclad (cladribine tablets; Merck, Darmstadt, Germany) showed high rates of treatment persistence and low rates of switching to other disease-modifying therapies (DMTs). These results from an
- Agamree Receives FDA Approval as First “Dissociative Steroidal Anti-Inflammatory” to Treat Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/agamree-receives-fda-approval-as-first-dissociative-steroidal-anti-inflammatory-to-treat-duchenne-muscular-dystrophy/2470327/Agamree (vamorolone; Catalyst Pharmaceuticals, Coral Gables, FL) has received Food and Drug Administration (FDA) approval as an oral suspension 40 mg/mL to treat Duchenne Muscular Dystrophy (DMD) in patients aged 2 years and older. Agamree was developed by Santhera Pharmaceuticals (Pratteln, Swit
- Donanemab Treatment Effects in Early Stages of Alzheimer Disease Detailed in New Post-Hoc Analysis from TRAILBLAZER-ALZ 2https://practicalneurology.com/news/donanemab-treatment-effects-in-early-stages-of-alzheimer-disease-detailed-in-new-post-hoc-analysis-from-trailblazer-alz-2/2470324/According to post-hoc analyses of data from the TRAILBLAZER-ALZ 2 clinical trial (NCT04437511), people with baseline characteristics indicative of earlier stages of Alzheimer disease (AD), including lower tau PET, younger age, and plasma phosphorylated tau at threonine 217 (p-tau217) levels, show
- Dr. Anthony Lang Presents Novel SynNeurGe Model of Parkinson Disease Identificationhttps://practicalneurology.com/news/dr-anthony-lang-presents-novel-synneurge-model-of-parkinson-disease-identification/2470321/Dr. Anthony Lang, Professor of Neurology and Jack Clark Chair for Parkinson’s Disease Research at the University of Toronto, presented a new model for identifying Parkinson disease (PD) at the 26th World Congress of Neurology. The new model, SynNeurGe, is a framework consisting of 3 distinc
- Novel Monoclonal Antibody Which Targets Tau Protein Accumulation Receives IND Clearance from FDAhttps://practicalneurology.com/news/novel-monoclonal-antibody-which-targets-tau-protein-accumulation-receives-ind-clearance-from-fda/2470293/Oscotec (Seognam, South Korea) and ADEL (Seoul, South Korea) announced that their investigational new drug (IND) application for ADEL-Y01, a novel IgG1 class type monoclonal humanized antibody that binds to tau protein acetylated at lysine-280, was cleared by the Food and Drug Administration (FDA
- Is Infertility Treatment Associated with Stroke-Related Hospitalization?https://practicalneurology.com/news/is-infertility-treatment-associated-with-stroke-related-hospitalization/2470287/According to results of a study published in JAMA Network Open, infertility treatment is associated with an increased risk of hospitalization from hemorrhagic and ischemic stroke within 1 year of delivery. Patients receiving infertility treatment had an overall 66% increased risk of bein
- Highlights from the 1st Spinal Cord Injury Investor Symposium: Cell Transplant Approacheshttps://practicalneurology.com/news/highlights-from-the-1st-spinal-cord-injury-investor-symposium-cell-transplant-approaches/2470286/Spinal cord injury (SCI) affects an estimated 17,500 individuals each year in the United States, and less than 1% of those with SCI will experience complete neurologic recovery upon hospital discharge. Rehabilitation, assistive devices, medications, and surgery only provide benef
- Highlights from the 1st Spinal Cord Injury Investor Symposium: The 3-Pillar Research Strategy of the Christopher & Dane Reeve Foundationhttps://practicalneurology.com/news/highlights-from-the-1st-spinal-cord-injury-investor-symposium-the-3-pillar-research-strategy-of-the-christopher-dane-reeve-foundation/2470284/Spinal cord injury (SCI) affects an estimated 17,500 individuals each year in the United States, and less than 1% of those with SCI will experience complete neurologic recovery upon hospital discharge. Rehabilitation, assistive devices, medications, and surgery only provide benef
- Encouraging Results for Investigational Cellular Therapy for Parkinson Diseasehttps://practicalneurology.com/news/encouraging-results-for-investigational-cellular-therapy-for-parkinson-disease/2470281/Results of a phase 1 study (NCT04802733) presented at the 2023 International Congress of Parkinson’s Disease and Movement Disorders revealed positive safety and tolerability outcomes through year 1 for bemdaneprocel (BRT-DA0l; BlueRock Therapeutics, Cambridge, MA) in patients with Parkinson
- Comparison of Levodopa vs Dopamine Agonists vs MOA-Bs in Patients with Early PDhttps://practicalneurology.com/news/comparison-of-levodopa-vs-dopamine-agonists-vs-moa-bs-in-patients-with-early-pd/2470279/Final results from the 15-year PD MED EARLY study demonstrated improved quality of life (QoL) scores for patients with early Parkinson disease (PD) initially treated with levodopa (LD) compared with LD-sparing therapies (dopamine agonists [DA] and inhibitors of type B monoamine oxidase [MOA-B]).